{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:10:21Z","timestamp":1791051021631,"version":"4.1.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2006,8,31]]},"DOI":"10.2217\/14796694.2.4.441","type":"journal-article","created":{"date-parts":[[2006,8,21]],"date-time":"2006-08-21T14:36:30Z","timestamp":1156170990000},"page":"441-448","source":"Crossref","is-referenced-by-count":11,"title":["Nelarabine: Efficacy In the Treatment of Clinical Malignancies"],"prefix":"10.1080","volume":"2","author":[{"given":"Andrew M","family":"Roecker","sequence":"first","affiliation":[{"name":"Ohio Northern University College of Pharmacy, 525 South Main Street, Department of Pharmacy Practice, Ada, OH45810, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery C","family":"Allison","sequence":"additional","affiliation":[{"name":"Ohio Northern University College of Pharmacy, 525 South Main Street, Department of Pharmacy Practice, Ada, OH45810, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Kisor","sequence":"additional","affiliation":[{"name":"Ohio Northern University College of Pharmacy, 525 South Main Street, Department of Pharmaceutical & Biomedical Sciences, Ada, OH45810, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2006,8,21]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.123"},{"key":"e_1_3_1_3_5_1","first-page":"3352","article-title":"2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe CU","year":"1995","unstructured":"Lambe CU , AverettDR, PaffMT, ReardonJE, WilsonJG, KrenitskyTA: 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res.55, 3352\u20133356 (1995).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_6_1","first-page":"4937","article-title":"Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.","volume":"59","author":"Rodriguez CO","year":"1999","unstructured":"Rodriguez CO , GandhiV: Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.Cancer Res.59, 4937\u20134943 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_7_1","first-page":"3000","article-title":"Arabinosyl-guanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.","volume":"62","author":"Rodriguez CO","year":"2002","unstructured":"Rodriguez CO , MitchellBS, AyresM, ErikssonS, GandhiV: Arabinosyl-guanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.Cancer Res.62, 3000\u20133005 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_8_1","first-page":"1517","article-title":"Cytotoxicity, metabolism, and mechanism of action of 2\u00b4,2\u00b4-difluorodeoxyguanosine in Chinese hamster ovary cells","volume":"55","author":"Gandhi V","year":"1995","unstructured":"Gandhi V , MineishiS, HuangPet al.: Cytotoxicity, metabolism, and mechanism of action of 2\u00b4,2\u00b4-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res.55, 1517\u20131524 (1995).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.10.5011"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-1248-2_29"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0317"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"e_1_3_1_3_13_1","unstructured":"GlaxoSmithKline: Arranon\u00ae (nelarabine) injection for intravenous use (product information). Research Triangle Park NC USA (2005)."},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3607"},{"key":"e_1_3_1_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"e_1_3_1_3_16_1","first-page":"2107","article-title":"Pharmacological and biochemical strategies to increase accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells.","volume":"3","author":"Rodriguez COR","year":"1997","unstructured":"Rodriguez COR , LeghaJK, EsteyE, KeatingMJ, GandhiV: Pharmacological and biochemical strategies to increase accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells.Clin. Cancer Res.3, 2107\u201313 (1997).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"e_1_3_1_3_18_1","first-page":"742","article-title":"A Phase\u00a0II study of 2-amino-9-\u03b2-D-arabinosyl-6methoxy-9H-purine (506U78) in patients with relapse of refractory T-lineage acute lymphoblastic leukemias (ALL) of lymphoblastic lymphoma (LBL) (abstract): CALGB Study 19801","volume":"100","author":"DeAngelo DJ","year":"2002","unstructured":"DeAngelo DJ , YuD, DodgeRKet al.: A Phase\u00a0II study of 2-amino-9-\u03b2-D-arabinosyl-6methoxy-9H-purine (506U78) in patients with relapse of refractory T-lineage acute lymphoblastic leukemias (ALL) of lymphoblastic lymphoma (LBL) (abstract): CALGB Study 19801. Blood100, 742 (2002).","journal-title":"Blood"},{"key":"e_1_3_1_3_19_1","volume-title":"45th Annual Meeting American Society of Hematology.","author":"Goy A","unstructured":"Goy A , BleyerA, HagemeisterFet al.: Phase\u00a0II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy. Presented at:45th Annual Meeting American Society of Hematology. CA, USA, 6\u20139 December 2003."},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.426"},{"key":"e_1_3_1_3_21_1","unstructured":"FDA: Arranon\u00ae (nelarabine) Oncology Drug Advisory Committee Briefing Document: Clinical and Statistical. 21\u2013877 (2005)."},{"key":"e_1_3_1_3_22_1","unstructured":"American Cancer Society: Cancer facts and figures 2006. GA USA (2006)."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.2.4.441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:55Z","timestamp":1719124975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.2.4.441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,21]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8,31]]}},"alternative-id":["10.2217\/14796694.2.4.441"],"URL":"https:\/\/doi.org\/10.2217\/14796694.2.4.441","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,21]]}}}